dapsone has been researched along with Deficiency, Glucosephosphatase in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the risk of hemolysis in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency who were treated for acne vulgaris with either dapsone gel, 5% (dapsone gel), or vehicle gel." | 9.13 | Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008) |
| "To evaluate the risk of hemolysis in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency who were treated for acne vulgaris with either dapsone gel, 5% (dapsone gel), or vehicle gel." | 5.13 | Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008) |
| "Topical dapsone gel 5% is indicated for the treatment of acne vulgaris and has been marketed since late 2008." | 3.76 | Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? ( Webster, GF, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piette, WW | 1 |
| Taylor, S | 1 |
| Pariser, D | 1 |
| Jarratt, M | 1 |
| Sheth, P | 1 |
| Wilson, D | 1 |
| Tiono, AB | 1 |
| Dicko, A | 1 |
| Ndububa, DA | 1 |
| Agbenyega, T | 1 |
| Pitmang, S | 1 |
| Awobusuyi, J | 1 |
| Pamba, A | 1 |
| Duparc, S | 1 |
| Goh, LE | 1 |
| Harrell, E | 1 |
| Carter, N | 1 |
| Ward, SA | 1 |
| Greenwood, B | 1 |
| Winstanley, PA | 1 |
| Webster, GF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%.[NCT00243542] | Phase 4 | 64 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for dapsone and Deficiency, Glucosephosphatase
| Article | Year |
|---|---|
Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Adult; Anemia, Hemolytic; Child; Cross-Over Studies; Dapsone; Dermatologi | 2008 |
Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Africa South of the Sahara; Animals; Antimalarials; Artemisinins; Artesunate; Chi | 2009 |
1 other study available for dapsone and Deficiency, Glucosephosphatase
| Article | Year |
|---|---|
Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients?
Topics: Acne Vulgaris; Administration, Cutaneous; Clinical Trials as Topic; Dapsone; Dermatologic Agents; Dr | 2010 |